title: [Tuberculous lymphadenitis after successful treatment of hepatitis C].
authors.forename: Javier
authors.initials: J
authors.lastname: Velasco
authors.forename: Silvia
authors.initials: S
authors.lastname: González
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016207:Cytokines / Q000096:biosynthesis; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D055985:Latent Tuberculosis / Q000150:complications*; D008297:Male; D009169:Mycobacterium tuberculosis / Q000254:growth & development / Q000502:physiology; D009894:Opportunistic Infections / Q000209:etiology*; D010154:Pakistan / Q000453:epidemiology; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D014388:Tuberculosis, Lymph Node / Q000209:etiology*
chemical_list: D000998:Antiviral Agents; D016207:Cytokines; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a